Trials / Completed
CompletedNCT00442533
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms.
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Radio Isotope Therapy of America · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Indium-111 pentetreotide | 4 cycles of 500 mCi treatments every 10-12 weeks |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2014-08-30
- Completion
- 2015-12-28
- First posted
- 2007-03-02
- Last updated
- 2023-04-03
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00442533. Inclusion in this directory is not an endorsement.